AMCP CEO Susan Cantrell Addresses Complex Causes of High Drug Prices and Advocates for Multi-Stakeholder Solutions in US Healthcare
In this first part of a video series, Susan Cantrell, CEO of AMCP, discussed root causes of high drug prices, its impact on underserved communities and Medicare price negotiation, emphasizing AMCP's actions and the role of decreasing drug prices for equity.
AMCP CEO Susan Cantrell spoke with Managed Healthcare Executive about the challenges of pinpointing specific causes for high drug prices.
Cantrell emphasized the crucial role of innovation in driving prescription drug costs, sharing the exciting advancements in therapies for long-standing health issues. However, she did caution against some policy solutions that might intervene in any innovations.
Additionally, she stressed the importance of payment models, supporting the Medicaid Value-Based Payments for Patients (MVP) Act to enhance Medicaid patients' access to high-cost therapies.
At AMCP, her team focuses on advocating for the appropriate use of medications and promoting generics and biosimilars to address cost concerns.
When asked about the significant increase in existing prescription drug costs, Cantrell acknowledged the steady rise but stressed the complexity of data and sources in providing precise figures.
Lastly, Cantrell highlighted the need for a multi-stakeholder approach involving patients, health plans, benefit managers, employers, manufacturers and healthcare delivery systems to find effective solutions that balance access, affordability and innovation.
Patients Express Concerns Over Costs, Risks of Gene Therapies for Sickle Cell Disease
December 12th 2024Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene therapies for sickle cell disease, which offer great potential but have had slow uptake.
Read More
Jack Linehan of Epstein Becker Green Discusses Drug Coupons, Accumulators
July 9th 2020In this week's episode of Tuning Into The C-Suite podcast, Senior Editor Peter Wehrwein has a conversation with John "Jack" Linehan, a lawyer for Epstein Becker Green, about coupons and accumulators. Jack is an expert on drug distribution and reimbursement, and few people know as much about coupons and accumulators as he does. Peter and Jack go over some of the basics, who is advantaged and disadvantaged, and then dive into some the details on CMS regulations and how recent proposed changes to Medicaid best price rules would, if finalized, affect coupons and accumulators.
Listen
